Table 6. Mean cortical measurement for longitudinal cohort participants with full dynamic PiB.
| MC_CER | MC_BS | MC_CW | MC_TW | MCRSF_CER | MCRSF_BS | MCRSF_CW | MCRSF_TW | MCBP | MCBPRSF | |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 1.83±0.59 | 1.18±0.35 | 1.12±0.31 | 1.02±0.16 | 2.80±1.33 | 1.50±0.64 | 1.60±0.71 | 1.54±0.62 | 0.62±0.45 | 1.33±0.93 |
| follow-up | 1.89±0.58 | 1.22±0.35 | 1.16±0.32 | 1.03±0.15 | 2.93±1.33 | 1.58±0.66 | 1.71±0.75 | 1.60±0.62 | 0.67±0.45 | 1.43±0.95 |
| Delta | 0.05±0.13 | 0.04±0.06 | 0.04±0.05 | 0.01±0.04 | 0.14±0.29 | 0.09±0.09 | 0.11±0.12 | 0.06±0.11 | 0.05±0.10 | 0.10±0.22 |
| p (follow-up vs. Baseline) | 6.34E-02 | 1.98E-03 | 4.47E-04 | 8.39E-02 | 3.33E-02 | 2.02E-04 | 1.68E-04 | 1.19E-02 | 2.91E-02 | 3.84E-02 |
| Rate | 0.02±0.09 | 0.02±0.03 | 0.02±0.03 | 0.00±0.02 | 0.05±0.17 | 0.04±0.05 | 0.05±0.06 | 0.03±0.05 | 0.02±0.05 | 0.04±0.11 |
| Effect Size | 0.23 | 0.62 | 0.71 | 0.25 | 0.33 | 0.85 | 0.82 | 0.49 | 0.33 | 0.34 |
| sample size (25% reduction in Rate) | 2286 | 333 | 251 | 2038 | 1171 | 177 | 188 | 519 | 1177 | 1097 |
| sample size (50% reduction in Rate) | 573 | 85 | 65 | 511 | 295 | 46 | 49 | 132 | 296 | 276 |
MC_CER = mean cortical region SUVR using cerebellar cortex as reference; MC_BS = mean cortical region SUVR using brainstem as reference; MC_CW = mean cortical region SUVR using core white matter as reference; MC_TW = mean cortical region SUVR using total white matter as reference; MCRSF_CER = mean cortical region SUVR using cerebellar cortex as reference with RSF partial volume correction; MCRSF_BS = mean cortical region SUVR using brainstem as reference with RSF partial volume correction; MCRSF_CW = mean cortical region SUVR using core white matter as reference with RSF partial volume correction; MCRSF_TW = mean cortical region SUVR using total white matter as reference with RSF partial volume correction; MCBP = mean cortical binding potential; MCBPRSF = mean cortical binding potential with RSF partial volume correction; delta = change in SUVR from baseline to follow-up; p is the strength of the difference between follow-up and baseline SUVRs based on a paired t-test; Rate = the annual rate of SUVR change; sample size is the estimated number of participants per arm needed to detect a 25% or a 50% reduction in amyloid accumulation rate due to treatment with 80% power and a two-tailed type-I error of p = 0.05 in a 12-month placebo-controlled randomized clinical trial.